Meeting
2011 ASCO Annual Meeting
Phase I trial of the first-in-class EGFR antibody mixture, Sym004, in patients with advanced solid tumors.
Authors
R. Dienstmann
Vall d'Hebron University Hospital, Barcelona, Spain
R. Dienstmann , A. W. Tolcher , K. P. Papadopoulos , D. W. Rasco , J. Tabernero , I. Brana , A. Piera , N. J. Skartved , H. Aladdin , J. Petersen , A. Patnaik
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics - Experimental Therapeutics
Track
Developmental Therapeutics
Sub Track
Other Novel Agents
Clinical Trial Registration Number
NCT01117428
Citation
J Clin Oncol 29: 2011 (suppl; abstr 3089)
Abstract #
3089
Poster Bd #
17F
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
A phase I trial of sequential dosing of sonidegib and pembrolizumab in advanced solid tumors (aST) and non–small-cell lung cancer (NSCLC).
First Author: Mohamed Shanshal
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Interim results of a first-in-human phase 1 study of Q-1802, a CLDN18.2/PD-L1 bsABs, in patients with relapsed or refractory solid tumors.
First Author: Wang Yk
Poster
2017 Gastrointestinal Cancers Symposium
Phase I/IB multicenter study of afatinib in combination with capecitabine in patients (pts) with refractory solid tumors and pancreatico-biliary cancers.
First Author: Amy E. Chang
Poster
2016 ASCO Annual Meeting
A first-in-human phase 1 study of GC1118, a novel monoclonal antibody inhibiting epidermal growth factor receptor (EGFR), in patients with advanced solid tumors.
First Author: Keun Wook Lee